Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-positive, PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.